{"id":"tobramycin-inhalant-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Wheezing"},{"rate":null,"effect":"Dysphonia"},{"rate":null,"effect":"Tinnitus"}]},"_chembl":{"chemblId":"CHEMBL3989564","moleculeType":"Small molecule","molecularWeight":"1425.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tobramycin inhalant products deliver the antibiotic directly to the lungs via aerosol, achieving high local concentrations in respiratory secretions. This formulation is particularly effective for treating chronic airway infections in cystic fibrosis patients, where it targets Pseudomonas aeruginosa and other susceptible pathogens that colonize the lungs. The inhalation route minimizes systemic exposure while maximizing therapeutic drug concentration at the site of infection.","oneSentence":"Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against aerobic gram-negative and some gram-positive bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:57.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic Pseudomonas aeruginosa airway infection in cystic fibrosis patients"},{"name":"Chronic suppressive therapy for gram-negative bacterial airway infections in cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT06093191","phase":"PHASE4","title":"Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2023-09-25","conditions":"Bronchiectasis Adult, Pseudomonas Aeruginosa Infection","enrollment":364},{"nctId":"NCT03066453","phase":"PHASE3","title":"Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2017-06-13","conditions":"Cystic Fibrosis","enrollment":23},{"nctId":"NCT03715322","phase":"PHASE3","title":"Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2018-10-26","conditions":"Bronchiectasis Adult, Pseudomonas Infections","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inhaled antibiotics"],"phase":"marketed","status":"active","brandName":"Tobramycin Inhalant Product","genericName":"Tobramycin Inhalant Product","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against aerobic gram-negative and some gram-positive bacteria. Used for Chronic Pseudomonas aeruginosa airway infection in cystic fibrosis patients, Chronic suppressive therapy for gram-negative bacterial airway infections in cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}